Biorestorative Therapies Inc (BRTX)

$1.97 -0.06 (-2.72%)
Market Cap 13.63M
Revenue (ttm) 150,000.00
Net Income (ttm) -14.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,613.33%
Debt to Equity Ratio 0.00
Volume 71,200
Avg Vol 67,610
Day's Range N/A - N/A
Shares Out 6.92M
Stochastic %K 76%
Beta 63.13
Analysts Strong Sell
Price Target $13.00

Latest News on BRTX

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

Dec 5, 2024, 6:45 AM EST - 6 weeks ago

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:53 PM EST - 2 months ago

BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

Nov 5, 2024, 7:10 AM EST - 2 months ago

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 3, 2024, 4:15 PM EDT - 3 months ago

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

Sep 19, 2024, 6:55 AM EDT - 4 months ago

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 11:26 PM EDT - 5 months ago

BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

Jul 23, 2024, 7:10 AM EDT - 6 months ago

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

Jun 27, 2024, 7:40 AM EDT - 7 months ago

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

Jun 17, 2024, 7:05 AM EDT - 7 months ago

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

Jun 13, 2024, 7:00 AM EDT - 7 months ago

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

Jun 4, 2024, 8:50 AM EDT - 8 months ago

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

May 24, 2024, 7:45 PM EDT - 8 months ago

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

May 15, 2024, 9:00 AM EDT - 8 months ago

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:08 PM EDT - 8 months ago

BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript

BioRestorative Therapies Provides First Quarter 2024 Business Update

May 14, 2024, 4:10 PM EDT - 8 months ago

BioRestorative Therapies Provides First Quarter 2024 Business Update

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

May 8, 2024, 7:30 AM EDT - 9 months ago

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 30, 2024, 4:15 PM EDT - 9 months ago

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

Apr 30, 2024, 7:30 AM EDT - 9 months ago

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

Apr 16, 2024, 7:45 AM EDT - 9 months ago

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Apr 8, 2024, 7:45 AM EDT - 10 months ago

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

Apr 3, 2024, 4:38 PM EDT - 10 months ago

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Apr 1, 2024, 7:45 AM EDT - 10 months ago

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

Mar 11, 2024, 4:15 PM EDT - 11 months ago

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting

Feb 14, 2024, 9:15 AM EST - 1 year ago

BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

Feb 6, 2024, 8:05 AM EST - 1 year ago

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

Feb 5, 2024, 7:30 AM EST - 1 year ago

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

Feb 1, 2024, 7:30 AM EST - 1 year ago

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

Dec 12, 2023, 9:15 AM EST - 1 year ago

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

Oct 9, 2023, 12:10 PM EDT - 1 year ago

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

Sep 18, 2023, 9:00 AM EDT - 1 year ago

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

Sep 12, 2023, 9:00 AM EDT - 1 year ago

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

Sep 8, 2023, 8:30 AM EDT - 1 year ago

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

Aug 30, 2023, 9:00 AM EDT - 1 year ago

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares

Aug 2, 2023, 9:00 AM EDT - 1 year ago

BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares

Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion

Jul 31, 2023, 8:05 AM EDT - 1 year ago

Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion

BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State

Jul 21, 2023, 7:10 AM EDT - 1 year ago

BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State

BioRestorative Therapies Announces $2.1 Million Registered Direct Offering

Jul 11, 2023, 8:30 AM EDT - 1 year ago

BioRestorative Therapies Announces $2.1 Million Registered Direct Offering

BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities

Jul 7, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities

BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes

Jun 27, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes

BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Jun 16, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It

Jun 15, 2023, 7:48 AM EDT - 1 year ago

Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It

BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease

Jun 12, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference

Jun 1, 2023, 9:15 AM EDT - 1 year ago

BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference

BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing

May 31, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing

BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

May 15, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market

May 12, 2023, 7:15 AM EDT - 1 year ago

A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company's Phase 2 Clinical Trial

May 8, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company's Phase 2 Clinical Trial

BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City

May 4, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City

BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100

Apr 24, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100